Search

Aurinia Pharmaceuticals Inc

Lezárt

SzektorEgészségügy

16.55 -1.9

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

16.51

Maximum

16.87

Fő mutatók

By Trading Economics

Bevétel

3.1M

37M

Értékesítés

5.5M

83M

P/E

Szektor átlag

7.197

56.432

Egy részvényre jutó nyereség

0.28

Profit margin

44.958

Munkavállalók

128

EBITDA

4.8M

55M

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+6.51% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 3.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

310M

2.2B

Előző nyitás

18.45

Előző zárás

16.55

Hangulat hírek alapján

By Acuity

67%

33%

285 / 339 Rangsor szerint Healthcare

Aurinia Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 16. 19:22 UTC

News

Aurinia Pharmaceuticals Inc shares are significantly higher after reporting a substantial increase in quarterly revenue and a rise in net income from LUPKYNIS sales.

2026. szept. 15. 19:56 UTC

Aurinia Pharmaceuticals Inc. shares are trading lower amid broader market sentiment influenced by anticipated Federal Reserve rate hikes and rising Treasury yields.

2026. szept. 14. 20:07 UTC

Aurinia Pharmaceuticals shares are higher amid market volatility and inflation concerns ahead of the Federal Reserve's interest rate decision.

2026. szept. 10. 20:06 UTC

Aurinia Pharmaceuticals shares are lower today, influenced by broader market declines amid macroeconomic factors, including the European Central Bank's interest rate hike.

2026. szept. 9. 20:41 UTC

Aurinia Pharmaceuticals Inc shares are higher in after-market trading, showing increased investor interest despite no specific company news, remaining above their 20-day moving average.

2026. szept. 8. 23:36 UTC

Aurinia Pharmaceuticals Inc is trading lower in after-market hours, with no specific news identified to explain the movement. The stock remains within its one-month trading range.

2026. szept. 1. 20:08 UTC

Aurinia Pharmaceuticals is declining amid broader market losses and rising inflation concerns, with no specific company news identified to explain the movement.

2026. aug. 26. 20:08 UTC

News

Aurinia Pharmaceuticals shares are lower amid broader Biotechnology sector weakness. A Form 4 filing revealed a $355,000 insider share sale by Chief Legal Officer Stephen P. Robertson.

2026. aug. 25. 19:36 UTC

Aurinia Pharmaceuticals Inc is trading higher amid a positive market environment, despite pulling back from earlier session highs. No specific news was identified.

2026. aug. 24. 22:01 UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, continuing a trend of declines observed over the past three sessions. No specific news was identified.

2026. aug. 21. 23:06 UTC

Aurinia Pharmaceuticals Inc. shares are higher in after-market hours, reflecting routine trading activity and maintaining a position above the 20-day moving average.

2026. aug. 20. 21:46 UTC

Aurinia Pharmaceuticals Inc shares are trading lower in after-market hours. No specific news was identified to explain the decline.

2026. aug. 19. 23:02 UTC

News

Aurinia Pharmaceuticals settled patent litigation with Teva, securing exclusivity for voclosporin until December 2036. Shares rose in after-hours trading following the announcement.

2026. aug. 18. 19:56 UTC

Aurinia Pharmaceuticals Inc is trading higher today, though no specific news has been identified. Rising Treasury yields may pose challenges for equities.

2026. aug. 17. 20:02 UTC

Social Media

Aurinia Pharmaceuticals shares are lower amid broader market declines and rising crude oil prices, despite some social media chatter about potential buyout interest.

2026. aug. 14. 19:26 UTC

Aurinia Pharmaceuticals shares are higher today, rebounding after earlier volatility amid broader market concerns over disappointing U.S. retail sales figures.

2026. aug. 13. 19:56 UTC

News

Aurinia Pharmaceuticals shares are lower today, despite ongoing sales growth of Lupkynis and a recent acquisition of Kezar Life Sciences.

2026. aug. 11. 20:06 UTC

Aurinia Pharmaceuticals Inc shares are trading lower today, continuing a trend of three consecutive daily declines amid no specific news to explain the movement.

2026. aug. 10. 20:06 UTC

News

Aurinia Pharmaceuticals shares decline following multiple downgrades from research firms, despite Royal Bank of Canada raising its price target to $16.00.

2026. aug. 7. 19:16 UTC

News

Aurinia Pharmaceuticals shares are lower today, despite earlier gains. RBC Capital raised the price target to $16.00 from $15.00, maintaining a Sector Perform rating.

2026. aug. 6. 20:02 UTC

Event
News

Aurinia Pharmaceuticals reported second-quarter EPS of $0.28, exceeding estimates. The stock is higher today amid strong financial results and reaffirmed revenue guidance for 2026.

2026. aug. 4. 19:46 UTC

Aurinia Pharmaceuticals Inc is trading higher amid a positive market environment and a decline in crude oil prices, which may benefit consumer spending.

2026. aug. 3. 22:01 UTC

Aurinia Pharmaceuticals shares are higher in after-market hours, despite being below the 20-day moving average and three prior lower daily closes.

2026. aug. 1. 00:01 UTC

Aurinia Pharmaceuticals Inc is trading lower in after-market hours, reflecting a significant decline in the overall market and ongoing weakness in performance metrics.

2026. júl. 31. 21:01 UTC

Aurinia Pharmaceuticals Inc is higher in after-market trading, rising notably from a flat start. The stock remains below its 20-day moving average.

2026. júl. 30. 20:31 UTC

Aurinia Pharmaceuticals Inc. shares rose in after-market trading, following a broader market trend as the S&P 500 also gained. No specific news was identified.

2026. júl. 29. 22:01 UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, showing notable weakness and trading below its 20-day moving average. No specific news was identified.

2026. júl. 28. 19:36 UTC

Aurinia Pharmaceuticals shares are lower, reflecting volatility amid broader market conditions. The stock is trading significantly below its 20-day moving average.

2026. júl. 27. 19:16 UTC

Aurinia Pharmaceuticals is trading higher, benefiting from lower oil prices and easing inflation concerns ahead of the Federal Reserve meeting later this week.

2026. júl. 24. 18:26 UTC

Aurinia Pharmaceuticals is trading higher, despite pulling back from earlier gains. Broader market volatility, influenced by declining oil prices, impacts sentiment.

Társak összehasonlítása

Árváltozás

Aurinia Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

6.51% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 18 USD  6.51%

Magas 21 USD

Alacsony 16 USD

3 Wall Street elemző 12 hónapos célárain alapulva a(z)Aurinia Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

3 ratings

2

Vétel

1

Tartás

0

Eladás

Hangulat

By Acuity

285 / 339 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bearish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.